Immunitybio inc (IBRX) - News Archive

N-803 Combined with Neutralizing Antibodies Shows Promise in HIV Viral Control: A Potential Breakthrough in Antiretroviral TherapyIn a recent publication in the online issue of Science, First Release, ImmunityBio, a cli...

In a groundbreaking pilot study, ImmunityBio has announced significant findings indicating the potential of their immunotherapy drug, N-803, combined with natural killer (NK) cells in reducing the viral load in individu...

In an exciting development for the field of cancer immunotherapy, ImmunityBio (NASDAQ: IBRX) has announced the completion of enrollment and initial follow-up for the safety portions of a clinical trial focusing on parti...

In a significant development in the oncology world, ImmunityBio, Inc. - a clinical-stage immunotherapy company, disclosed that the quality-of-life study conducted in BCG-unresponsive bladder cancer trail has illustrated...

ImmunityBio Secures $320 Million Investment from Oberland Capital, Boosting Commercialization EffortsCULVER CITY, Calif. - ImmunityBio, a leading clinical-stage immunotherapy company, announced a game-changing developme...